In this article I will tell you about the Pharma Franchise Model and how it is different from other franchise models. Along with Pharma Franchise, I will drop you some basic knowledge about the entire franchise model. Franchise marketing meaning varies from industry to industry. A franchise is a model of distribution and represents the most common business structure that enables the franchisor to capture recurring business from their franchisees. The franchisees are then able to earn profits from the same set of rules, systems and standardized products sold by other franchises across the country. In today's world of marketing, franchising has emerged as a lucrative option for new ventures as it simplifies and streamline the process of starting a business. With so much advanced equipment, efficient manpower, trained professionals etc., many entrepreneurs find it financially rewarding to take up a franchise business. What is Franchising? Franchising is a business strategy that involv
Schedules: Schedule A, Schedule B, Schedule C, Schedule D, Schedule E1, Schedule F, Schedule G, Schedule H, Schedule H1, Schedule I, Schedule J, Schedule K, Schedule L1, Schedule M, Schedule M1, Schedule M2, Schedule M3, Schedule N, Schedule O, Schedule P, Schedule Q, Schedule R, Schedule S, Schedule T, Schedule U, Schedule V, Schedule W, Schedule X, Schedule Y
Schedule Y describes the requirements and guidelines for permission to import and / or manufacture of new drugs for sale or to undertake clinical trials.
1.
Application for Permission
2.
Clinical Trial
I.
Approval for clinical trial
II.
Responsibilities of Sponsor
III.
Responsibilities of the Investigator(s)
IV.
Informed Consent
V.
Responsibilities of the Ethics Committee
VI.
Human Pharmacology (Phase I)
VII.
Therapeutic exploratory trials (Phase II)
VIII.
Therapeutic confirmatory trials (Phase III)
IX.
Post Marketing Trials (Phase IV)
3.
Studies in special populations
I.
Geriatrics
II.
Paediatrics
III.
Pregnant or nursing women
IV.
Post Marketing Surveillance
V.
Special studies: Bioavailability /
Bioequivalence Studies
Appendix I: Data to be submitted along with the application to conduct clinical trials/import/manufacture of new drugs for marketing in the country
Appendix IA: Data required to be submitted by an applicant for grant of permission to import and / or manufacture a new drug already approved in the country
Appendix IB: Data to be submitted along with application to conduct clinical trial or import or manufacture of a phytopharmaceutical drug in the country
Appendix II: Structure, contents and format for clinical study reports
Appendix III: Animal toxicology (non-clinical toxicity studies)
Appendix IV: Animal Pharmacology
Appendix V: Informed Consent
Appendix VI: Fix Dose Combinations (FDCs)
Appendix VII: Undertaking by Investigator
Appendix VIII: Ethics Committee
Appendix IX: Stability Testing of New Drugs
Appendix X: Contents of the proposed protocol for conducting clinical trials
Appendix XI: Data Elements for reporting serious adverse events occuring in a clinical trial
Appendix XII: Compensation in case of injury or death during clinical trial
For more detail refer Drug and Cosmetic Act
Comments
Post a Comment